pre-miRNA Information
pre-miRNA hsa-mir-664a   
Genomic Coordinates chr1: 220200538 - 220200619
Description Homo sapiens miR-664 stem-loop
Comment This miRNA sequence overlaps an annotated snoRNA, ACA38b. However, both miR and miR* sequences are identified in reference , and the sequence is homologous with rat mir-664.
RNA Secondary Structure

Mature miRNA Information
Mature miRNA hsa-miR-664a-3p
Sequence 49| UAUUCAUUUAUCCCCAGCCUACA |71
Evidence Experimental
Experiments Illumina
DRVs in miRNA
Mutant ID Mutant Position Mutant Source
COSN30457627 12 COSMIC
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs1478242335 2 dbSNP
rs1042905485 5 dbSNP
rs908858734 6 dbSNP
rs1229753248 8 dbSNP
rs770101636 12 dbSNP
rs746047168 14 dbSNP
rs1170225715 15 dbSNP
rs1404740911 16 dbSNP
rs1393962832 17 dbSNP
rs1377901643 18 dbSNP
rs1313271494 19 dbSNP
rs1416447585 20 dbSNP
rs1368463251 21 dbSNP
rs1167925254 22 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
miRNAs in Extracellular Vesicles
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol CTBP1   
Synonyms BARS
Description C-terminal binding protein 1
Transcript NM_001012614   
Other Transcripts NM_001328   
Expression
Putative miRNA Targets on CTBP1
3'UTR of CTBP1
(miRNA target sites are highlighted)
>CTBP1|NM_001012614|3'UTR
   1 CCCGGGAGGAGCTCTCCAGCCTCGGCGCCTGGGCAGAGGGCCCGGAAACCCTCGGACCAGAGTGTGTGGAGGAGGCATCT
  81 GTGTGGTGGCCCTGGCACTGCAGAGACTGGTCCGGGCTGTCAGGAGGCGGGAGGGGGCAGCGCTGGGCCTCGTGTCGCTT
 161 GTCGTCGTCCGTCCTGTGGGCGCTCTGCCCTGTGTCCTTCGCGTTCCTCGTTAAGCAGAAGAAGTCAGTAGTTATTCTCC
 241 CATGAACGTTCTTGTCTGTGTACAGTTTTTAGAACATTACAAAGGATCTGTTTGCTTAGCTGTCAACAAAAAGAAAACCT
 321 GAAGGAGCATTTGGAAGTCAATTTGAGGTTTTTTTTTTTGTTTTTTTTTTTTTTGTATGTTGGAACGTGCCCCAGAATGA
 401 GGCAGTTGGCAAACTTCTCAGGACAATGAATCCTTCCCGTTTTTCTTTTTATGCCACACAGTGCATTGTTTTTTCTACCT
 481 GCTTGTCTTATTTTTAGAATAATTTAGAAAAACAAAACAAAGGCTGTTTTTCCTAATTTTGGCATGAACCCCCCCTTGTT
 561 CCAAATGAAGACGGCATCACGAAGCAGCTCCAAAAGGAAAAGCTTGGGCGGTGCCCAGCGTGCCCGCTGCCCATCGACGT
 641 CTGTCCTGGGGACGTGGAGGGTGGCAGCGTCCCCGCCTGCACCAGTGCCGTCCTGCTGATGTGGTAGGCTAGCAATATTT
 721 TGGTTAAAATCATGTTTGTGACTGTAACCATTTGTATGAATTATTTTAAAGAAATAAAAATCCTGGAAAGAGCCAGCGTG
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1
miRNA  3' acauccGACCCCUAUUUACUUAu 5'
                ||  |||  ||||||| 
Target 5' aaacttCTCAGGA-CAATGAATc 3'
411 - 432 148.00 -6.70
2
miRNA  3' acAUCCGACC---CCU----AUUUACUUau 5'
            || |:|||   | :     :|||||:  
Target 5' tgTATGTTGGAACGTGCCCCAGAATGAGgc 3'
374 - 403 107.00 -8.10
3
miRNA  3' acAUCCGACC---------CCUA-UUUACUuau 5'
            |||||| |         || | |||| |   
Target 5' ggTAGGCTAGCAATATTTTGGTTAAAATCAtgt 3'
703 - 735 85.00 -10.49
DRVs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
COSN18729340 4 COSMIC
COSN30120110 8 COSMIC
COSN24384263 38 COSMIC
COSN29735125 163 COSMIC
COSN21522570 173 COSMIC
COSN15663077 359 COSMIC
COSN16155822 361 COSMIC
COSN17413524 522 COSMIC
COSN31531424 609 COSMIC
COSN30176898 643 COSMIC
COSN26550754 673 COSMIC
COSN25125502 689 COSMIC
COSN6793896 743 COSMIC
COSN31609141 771 COSMIC
SNPs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
rs1422330706 1 dbSNP
rs752660628 3 dbSNP
rs968456186 4 dbSNP
rs1460790640 5 dbSNP
rs552180452 5 dbSNP
rs1376031386 6 dbSNP
rs1172734455 11 dbSNP
rs1019998811 12 dbSNP
rs1391827412 13 dbSNP
rs1171393348 14 dbSNP
rs767750268 16 dbSNP
rs1417385069 17 dbSNP
rs1183702998 21 dbSNP
rs375089554 23 dbSNP
rs1257406162 24 dbSNP
rs865862007 26 dbSNP
rs371763271 27 dbSNP
rs1252312285 30 dbSNP
rs766641046 32 dbSNP
rs998478862 33 dbSNP
rs763015951 34 dbSNP
rs1334595529 35 dbSNP
rs368867475 36 dbSNP
rs1045466 37 dbSNP
rs1234622210 43 dbSNP
rs1005969919 44 dbSNP
rs551713236 51 dbSNP
rs115317882 53 dbSNP
rs1418830378 54 dbSNP
rs1047212435 61 dbSNP
rs1045469 79 dbSNP
rs1268746803 86 dbSNP
rs929792169 91 dbSNP
rs773751101 92 dbSNP
rs541511602 95 dbSNP
rs907349261 97 dbSNP
rs1057374943 112 dbSNP
rs937249430 113 dbSNP
rs529846447 115 dbSNP
rs927203620 118 dbSNP
rs978415667 128 dbSNP
rs947087201 129 dbSNP
rs1451818872 135 dbSNP
rs1045470 136 dbSNP
rs887794181 141 dbSNP
rs1049051514 142 dbSNP
rs1361236258 149 dbSNP
rs562305900 151 dbSNP
rs1236694612 152 dbSNP
rs988540959 156 dbSNP
rs956858198 157 dbSNP
rs1229425802 158 dbSNP
rs1036946943 163 dbSNP
rs1029804010 164 dbSNP
rs765714654 167 dbSNP
rs1388454871 169 dbSNP
rs1284954515 170 dbSNP
rs1218230105 171 dbSNP
rs1255285366 173 dbSNP
rs964290027 175 dbSNP
rs1018951262 176 dbSNP
rs1257926970 180 dbSNP
rs1005544211 181 dbSNP
rs1421556763 182 dbSNP
rs888488723 185 dbSNP
rs1302016766 188 dbSNP
rs1358678602 192 dbSNP
rs1025716676 194 dbSNP
rs1449323864 197 dbSNP
rs1305118102 200 dbSNP
rs181483701 201 dbSNP
rs895921251 203 dbSNP
rs1156441722 206 dbSNP
rs1377238695 209 dbSNP
rs1453573198 210 dbSNP
rs1277493844 219 dbSNP
rs1311104653 220 dbSNP
rs932379883 222 dbSNP
rs1378589819 223 dbSNP
rs765360395 225 dbSNP
rs989742813 239 dbSNP
rs955726735 242 dbSNP
rs544119555 245 dbSNP
rs1056926063 247 dbSNP
rs1424465546 248 dbSNP
rs1032361833 253 dbSNP
rs937177832 256 dbSNP
rs1353322752 259 dbSNP
rs905770395 260 dbSNP
rs576753551 264 dbSNP
rs1332418934 268 dbSNP
rs1379585923 272 dbSNP
rs1043403735 275 dbSNP
rs1023113942 278 dbSNP
rs1366268640 279 dbSNP
rs4974572 291 dbSNP
rs1219355070 294 dbSNP
rs1303275589 304 dbSNP
rs1194526526 307 dbSNP
rs1258403830 309 dbSNP
rs947033471 311 dbSNP
rs1489307838 318 dbSNP
rs912930939 320 dbSNP
rs1212053551 325 dbSNP
rs1013008678 327 dbSNP
rs887828831 334 dbSNP
rs1204784810 337 dbSNP
rs376995762 341 dbSNP
rs1027731924 342 dbSNP
rs993944421 343 dbSNP
rs190712719 349 dbSNP
rs1037386363 350 dbSNP
rs1460257182 351 dbSNP
rs923017738 354 dbSNP
rs1321148492 357 dbSNP
rs374555956 359 dbSNP
rs1337792000 360 dbSNP
rs1436790168 360 dbSNP
rs909805634 360 dbSNP
rs1045480 361 dbSNP
rs1413822417 361 dbSNP
rs1218782310 362 dbSNP
rs1341820916 363 dbSNP
rs1452367395 363 dbSNP
rs943940976 364 dbSNP
rs890972667 365 dbSNP
rs555048849 369 dbSNP
rs1426470334 371 dbSNP
rs1474412245 371 dbSNP
rs1162996133 372 dbSNP
rs1415006173 373 dbSNP
rs1234269129 375 dbSNP
rs1358070933 375 dbSNP
rs937690023 375 dbSNP
rs1298711383 377 dbSNP
rs1305009007 377 dbSNP
rs186984898 378 dbSNP
rs1429286212 379 dbSNP
rs569490067 383 dbSNP
rs1171989752 385 dbSNP
rs1479053643 386 dbSNP
rs1371408927 387 dbSNP
rs1192516600 390 dbSNP
rs932413967 394 dbSNP
rs1217486054 403 dbSNP
rs1265464381 408 dbSNP
rs1484948173 428 dbSNP
rs976914355 433 dbSNP
rs140581613 436 dbSNP
rs964595256 438 dbSNP
rs911475152 439 dbSNP
rs11540633 445 dbSNP
rs76532252 449 dbSNP
rs572008054 459 dbSNP
rs1459810395 461 dbSNP
rs751473672 461 dbSNP
rs914358719 465 dbSNP
rs1262494083 470 dbSNP
rs1164626512 478 dbSNP
rs1378153918 482 dbSNP
rs1418530703 486 dbSNP
rs989857482 487 dbSNP
rs1361927105 490 dbSNP
rs1319825446 501 dbSNP
rs1412631578 502 dbSNP
rs77379446 507 dbSNP
rs1267920133 508 dbSNP
rs934348061 515 dbSNP
rs1450011076 517 dbSNP
rs924270159 519 dbSNP
rs984396054 522 dbSNP
rs1376384180 523 dbSNP
rs1241177380 524 dbSNP
rs952953013 526 dbSNP
rs982116635 535 dbSNP
rs1226028502 540 dbSNP
rs1342966961 543 dbSNP
rs1200381940 544 dbSNP
rs1340739576 545 dbSNP
rs1444468040 550 dbSNP
rs1025626835 551 dbSNP
rs563184205 553 dbSNP
rs527281344 554 dbSNP
rs564855534 556 dbSNP
rs566302187 570 dbSNP
rs1036216618 572 dbSNP
rs372329092 573 dbSNP
rs993584251 580 dbSNP
rs1416132091 583 dbSNP
rs1328982130 585 dbSNP
rs1399290585 590 dbSNP
rs962366565 609 dbSNP
rs147222661 610 dbSNP
rs1008565041 615 dbSNP
rs879622540 617 dbSNP
rs905713261 619 dbSNP
rs1181965351 620 dbSNP
rs1347708990 622 dbSNP
rs1042963534 625 dbSNP
rs1011421493 626 dbSNP
rs1257763517 627 dbSNP
rs772183606 629 dbSNP
rs1198864620 630 dbSNP
rs1252285589 636 dbSNP
rs1430916890 637 dbSNP
rs529712088 638 dbSNP
rs932997024 639 dbSNP
rs533092925 643 dbSNP
rs934401482 646 dbSNP
rs1242307904 647 dbSNP
rs1168448771 650 dbSNP
rs574402308 651 dbSNP
rs1439540178 653 dbSNP
rs1045369986 654 dbSNP
rs1333580978 656 dbSNP
rs1039235631 657 dbSNP
rs544035199 659 dbSNP
rs911409145 660 dbSNP
rs916204848 667 dbSNP
rs1356420165 668 dbSNP
rs926283257 669 dbSNP
rs771747026 671 dbSNP
rs1381532957 672 dbSNP
rs920733784 673 dbSNP
rs1487279454 674 dbSNP
rs952901006 675 dbSNP
rs972576408 678 dbSNP
rs1267370195 680 dbSNP
rs1490714222 683 dbSNP
rs532166377 689 dbSNP
rs565230395 690 dbSNP
rs1478012794 695 dbSNP
rs1172202507 698 dbSNP
rs1310472454 701 dbSNP
rs1449440360 704 dbSNP
rs1457533814 705 dbSNP
rs962113791 715 dbSNP
rs1392950288 722 dbSNP
rs1019373610 744 dbSNP
rs1298104485 746 dbSNP
rs960353672 754 dbSNP
rs953378588 771 dbSNP
rs1310945681 774 dbSNP
rs1035758218 780 dbSNP
rs1028221986 782 dbSNP
rs996688179 789 dbSNP
rs1213887599 794 dbSNP
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HEK293
Disease 1487.0
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... "PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1 ...

- Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods.

Article - Kishore S; Jaskiewicz L; Burger L; Hausser et al.
- Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions MCF7
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated ...

- Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology.

Article - Farazi TA; Ten Hoeve JJ; Brown M; et al.
- Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
Experimental Support 3 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HCT116
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in ERX177610. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_12 PAR-CLIP data was present in ERX177622. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_3_12 PAR-CLIP data was present in ERX177634. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_12 ...

- Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research.

Article - Krell J; Stebbing J; Carissimi C; Dabrowska et al.
- Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
Experimental Support 4 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions Prostate Tissue
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in SRX1760583. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP_A ...

- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.).

Article - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al.
- Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
CLIP-seq Support 1 for dataset GSM714644
Method / RBP PAR-CLIP / AGO2
Cell line / Condition HEK293 / completeT1, repA
Location of target site ENST00000382952.3 | 3UTR | AGGCAGUUGGCAAACUUCUCAGGACAAUG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 21572407 / GSE28865
CLIP-seq Viewer Link
CLIP-seq Support 2 for dataset SRR1045082
Method / RBP PAR-CLIP / AGO2
Cell line / Condition MCF7 / Untreated
Location of target site ENST00000382952.3 | 3UTR | CAAACUUCUCAGGACAAUG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 24398324 / SRX388831
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
GSE28260 Renal cortex and medulla -0.605 1.4e-2 -0.703 3.7e-3 13 Click to see details
GSE28544 Breast cancer 0.418 2.1e-2 0.633 4.5e-4 24 Click to see details
GSE38226 Liver fibrosis 0.29 1.0e-1 0.235 1.5e-1 21 Click to see details
GSE42095 Differentiated embryonic stem cells 0.195 1.9e-1 0.252 1.2e-1 23 Click to see details
GSE32688 Pancreatic cancer -0.081 3.3e-1 -0.057 3.8e-1 32 Click to see details
GSE26953 Aortic valvular endothelial cells 0.044 4.2e-1 0.060 3.9e-1 24 Click to see details
GSE38974 Chronic obstructive pulmonary disease -0.041 4.2e-1 -0.059 3.9e-1 25 Click to see details
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
KICH 0.475 0.01 0.465 0.01 25 Click to see details
KIRC 0.224 0.03 0.142 0.12 68 Click to see details
BLCA 0.369 0.07 0.342 0.08 18 Click to see details
PRAD 0.145 0.16 0.173 0.11 50 Click to see details
COAD 0.379 0.18 0.143 0.37 8 Click to see details
LUAD 0.29 0.18 0.322 0.15 12 Click to see details
ESCA 0.256 0.22 0.427 0.1 11 Click to see details
BRCA 0.074 0.25 0.119 0.14 84 Click to see details
HNSC 0.1 0.26 0.192 0.11 42 Click to see details
KIRP 0.115 0.27 0.181 0.16 32 Click to see details
LIHC 0.046 0.38 -0.023 0.44 49 Click to see details
THCA 0.04 0.38 0.157 0.12 59 Click to see details
UCEC -0.059 0.41 -0.061 0.4 19 Click to see details
CHOL 0.091 0.41 0.217 0.29 9 Click to see details
STAD 0.04 0.41 -0.098 0.3 32 Click to see details
LUSC 0.034 0.42 0.002 0.5 38 Click to see details
PCPG -0.211 0.43 -0.500 0.33 3 Click to see details
CESC 0.2 0.44 -0.500 0.33 3 Click to see details
PAAD 0.1 0.45 -0.400 0.3 4 Click to see details
PAAD 0.1 0.45 -0.400 0.3 4 Click to see details
PAAD 0.1 0.45 -0.400 0.3 4 Click to see details
88 hsa-miR-664a-3p Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT035824 HIAT1 major facilitator superfamily domain containing 14A 1 1
MIRT035826 FUS FUS RNA binding protein 1 1
MIRT069432 SIVA1 SIVA1 apoptosis inducing factor 2 2
MIRT071494 CALM1 calmodulin 1 2 2
MIRT100410 HSPA1B heat shock protein family A (Hsp70) member 1B 2 2
MIRT143469 CHD9 chromodomain helicase DNA binding protein 9 2 2
MIRT191113 ARF6 ADP ribosylation factor 6 2 2
MIRT235584 SNRPB2 small nuclear ribonucleoprotein polypeptide B2 2 8
MIRT339131 ARID1A AT-rich interaction domain 1A 2 2
MIRT437450 MAT1A methionine adenosyltransferase 1A 1 1
MIRT442234 BTD biotinidase 2 2
MIRT443321 SLC35G1 solute carrier family 35 member G1 2 2
MIRT443769 HLF HLF, PAR bZIP transcription factor 2 2
MIRT444352 KIAA1211 KIAA1211 2 2
MIRT456348 OLIG3 oligodendrocyte transcription factor 3 2 8
MIRT458866 CD55 CD55 molecule (Cromer blood group) 2 2
MIRT466169 TMED5 transmembrane p24 trafficking protein 5 2 2
MIRT470445 PPP1R15B protein phosphatase 1 regulatory subunit 15B 2 6
MIRT471524 PCGF3 polycomb group ring finger 3 2 6
MIRT477744 EDN1 endothelin 1 2 2
MIRT482885 CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 2 2
MIRT496336 PTPRT protein tyrosine phosphatase, receptor type T 2 2
MIRT497703 ARL6IP6 ADP ribosylation factor like GTPase 6 interacting protein 6 2 2
MIRT499068 CTBP1 C-terminal binding protein 1 2 4
MIRT500296 ZNF667 zinc finger protein 667 2 8
MIRT500506 ZBTB34 zinc finger and BTB domain containing 34 2 8
MIRT501964 MAPK8 mitogen-activated protein kinase 8 2 2
MIRT505457 SUB1 SUB1 homolog, transcriptional regulator 2 4
MIRT505955 RAN RAN, member RAS oncogene family 2 6
MIRT507512 DYNLL2 dynein light chain LC8-type 2 2 4
MIRT512953 MKI67 marker of proliferation Ki-67 2 2
MIRT520450 TSPAN2 tetraspanin 2 2 6
MIRT525997 MAGEL2 MAGE family member L2 2 2
MIRT526424 ZNF695 zinc finger protein 695 2 2
MIRT527364 KRTAP13-2 keratin associated protein 13-2 2 2
MIRT529612 H1F0 H1 histone family member 0 2 2
MIRT529811 TMLHE trimethyllysine hydroxylase, epsilon 2 2
MIRT530971 EXO5 exonuclease 5 2 4
MIRT531294 WNT7A Wnt family member 7A 2 2
MIRT531870 POF1B premature ovarian failure, 1B 2 2
MIRT532116 G6PC glucose-6-phosphatase catalytic subunit 2 2
MIRT533534 TPR translocated promoter region, nuclear basket protein 2 2
MIRT545934 ZBTB44 zinc finger and BTB domain containing 44 2 4
MIRT546649 RPS6KA5 ribosomal protein S6 kinase A5 2 2
MIRT548063 GNS glucosamine (N-acetyl)-6-sulfatase 2 2
MIRT548288 FAM3C family with sequence similarity 3 member C 2 4
MIRT551018 SPPL3 signal peptide peptidase like 3 2 2
MIRT551139 ZNF678 zinc finger protein 678 2 2
MIRT552398 ZNF487P zinc finger protein 487 1 1
MIRT555640 PHIP pleckstrin homology domain interacting protein 2 4
MIRT556267 MAPK6 mitogen-activated protein kinase 6 2 2
MIRT558864 CD2AP CD2 associated protein 2 2
MIRT559239 BEND4 BEN domain containing 4 2 2
MIRT559438 ARSJ arylsulfatase family member J 2 2
MIRT559793 ZNF415 zinc finger protein 415 2 2
MIRT562572 CBX6 chromobox 6 2 2
MIRT562741 ZNF83 zinc finger protein 83 2 2
MIRT564737 ZNF23 zinc finger protein 23 2 2
MIRT565174 LINC00598 long intergenic non-protein coding RNA 598 2 2
MIRT566301 PPM1A protein phosphatase, Mg2+/Mn2+ dependent 1A 2 2
MIRT571656 SERBP1 SERPINE1 mRNA binding protein 1 2 2
MIRT610720 NAV2 neuron navigator 2 2 2
MIRT611486 ADCYAP1R1 ADCYAP receptor type I 2 4
MIRT617118 KANK2 KN motif and ankyrin repeat domains 2 2 2
MIRT617836 SIGLEC10 sialic acid binding Ig like lectin 10 2 2
MIRT636145 VLDLR very low density lipoprotein receptor 2 2
MIRT638060 YAE1D1 Yae1 domain containing 1 2 4
MIRT640159 CDK13 cyclin dependent kinase 13 2 2
MIRT644257 WEE2 WEE1 homolog 2 2 2
MIRT646838 TLDC1 TBC/LysM-associated domain containing 1 2 2
MIRT653074 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 2 2
MIRT657671 GPR26 G protein-coupled receptor 26 2 2
MIRT660601 AP3M2 adaptor related protein complex 3 mu 2 subunit 2 2
MIRT668908 CREB1 cAMP responsive element binding protein 1 2 2
MIRT672685 GTF2H5 general transcription factor IIH subunit 5 2 2
MIRT680977 DCAF17 DDB1 and CUL4 associated factor 17 2 2
MIRT682271 RS1 retinoschisin 1 2 2
MIRT702058 RNMT RNA guanine-7 methyltransferase 2 2
MIRT707786 UNK unkempt family zinc finger 2 2
MIRT709238 RANGAP1 Ran GTPase activating protein 1 2 2
MIRT710119 MED23 mediator complex subunit 23 2 2
MIRT710675 ADAP2 ArfGAP with dual PH domains 2 2 2
MIRT712884 NIPBL NIPBL, cohesin loading factor 2 2
MIRT719015 HPGD 15-hydroxyprostaglandin dehydrogenase 2 2
MIRT723323 COLEC10 collectin subfamily member 10 2 2
MIRT724947 TXNL1 thioredoxin like 1 2 2
MIRT725535 EN2 engrailed homeobox 2 2 2
MIRT734156 FHL1 four and a half LIM domains 1 3 0
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-mir-664a Plx-4720 24180719 NSC757438 resistant High Thyroid Cancer cell line (8505c, BCPAP)
hsa-mir-664a Dabrafenib 44462760 NSC764134 approved sensitive cell line (A375)
hsa-mir-664a Fluorouracil 3385 NSC19893 approved resistant cell line (OE19)
hsa-miR-664a-3p Oxaliplatin 6857599 NSC266046 approved sensitive High Colorectal Cancer cell line (HT-29)
hsa-miR-664a-3p Oxaliplatin 6857599 NSC266046 approved resistant High Colorectal Cancer cell line (RKO)
hsa-miR-664a-3p Sorafenib 216239 NSC747971 approved resistant High Hepatocellular Carcinoma cell line (Huh-7)
hsa-miR-664a-3p Cisplatin 5460033 NSC119875 approved resistant High Gastric Cancer cell line (SGC7901)
hsa-miR-664a-3p Imatinib 5291 NSC743414 approved resistant High Chronic Myelogenous Leukemia cell line (K562)
hsa-miR-664a-3p Fulvestrant 17756771 NSC719276 approved resistant High Breast Cancer cell line (MCF-7)
hsa-miR-664a-3p Vemurafenib 42611257 NSC761431 approved sensitive High Melanoma cell line (A375)
hsa-miR-664a-3p Fluorouracil 3385 NSC19893 approved resistant High Colorectal Cancer cell line (HCT-116)
hsa-miR-664a-3p Temozolomide 5394 NSC362856 approved resistant cell line (U251)
hsa-miR-664a-3p Gefitinib 123631 NSC715055 approved resistant cell line (HCC827)
hsa-miR-664a-3p Osimertinib 71496458 NSC779217 approved resistant cell line (PC9)
hsa-miR-664a-3p Osimertinib 71496458 NSC779217 approved resistant cell line (HCC827)
hsa-miR-664a-3p Vemurafenib 42611257 NSC761431 approved sensitive cell line (LM17)
hsa-miR-664a-3p Vemurafenib 42611257 NSC761431 approved resistant cell line (LM11)
hsa-miR-664a-3p Vemurafenib 42611257 NSC761431 approved sensitive cell line (LM36)
hsa-miR-664a-3p Tamoxifen 2733525 NSC180973 approved resistant cell line (LCC2)
hsa-miR-664a-3p Fluorouracil 3385 NSC19893 approved resistant cell line (HCT15)
hsa-miR-664a-3p 4-Hydroxytamoxifen+Tamoxifen sensitive cell line (LY2)
hsa-miR-664a-3p Ethanol+Tamoxifen sensitive cell line (LY2)
hsa-miR-664a-3p Gemcitabine 60750 NSC613327 approved resistant cell line (MDA-231)
hsa-miR-664a-3p Cisplatin 5460033 NSC119875 approved sensitive cell line (A549)
hsa-miR-664a-3p Vemurafenib 42611257 NSC761431 approved sensitive cell line (LM16)
hsa-miR-664a-3p Gemcitabine 60750 NSC613327 approved resistant cell line (PANC-1) (100 ng/ml)
hsa-miR-664a-3p Gemcitabine 60750 NSC613327 approved resistant cell line (PANC-1) (1500 ng/ml)
hsa-miR-664a-3p Paclitaxel/Docetaxel/Vinorelbine/Doxorubicin/Etoposide resistant cell line (Bads-200)

Error report submission